Stocks›Healthcare›LGND

LGND

LIGAND PHARMACEUTICALS INCORPORATED

NasdaqResearch view

$301.52+0.83%

Sep 25 close · 1D EOD · Databento

HealthcarePharmaceutical PreparationsMid-capSEC EDGAR FY 2025-12-31

What happened

Daily closes · dots are Wire stories

1 story has a settled receipt so far (1 on the Wire). The record starts speaking at three.

What’s next

Expected around early November, going by its own filing history. The company has not announced a date yet. Its matching report came Nov 6, 2025 and Nov 7, 2024, before the open.

Last report

Aug 6, 2026−0.80%

before the open

Last 4, next close

median 5.93% either way

up 2 of 4

Every report since 2022 →

DateEventSourceNext close

Sep 4Ligand Pharmaceuticals (LGND): Massive XOMA Acquisition Doubles The Royalty BookYahoo FinanceYahoo Finance−1.43%
Aug 6Earnings release, before the open · 8-KSEC EDGARSEC EDGAR ↗−0.80%

Next close = the first close after the event against the close before it. Prior-session closes only; not a call, not advice.

Big days · last year

Daily closes · Databento EOD

16 big days: a close more than 3.99% from the one before, three times LGND’s median day (1.33%). On 0 of 16, its largest peers moved the same way at least half as far. We show what we hold, never a cause.

Shaded: since our stories began, May 26, 2026

16Jun 23, 2026
Jun 23, 2026Nothing in our recordNo LGND story, brief or results filing in our record that dayGroup +2.7% did not move with it
+2.7% did not move with itMRK +3.6 · JNJ +3.4 · ABBV +2.1 · LLY +0.5
+6.59%
15Jun 22, 2026
Jun 22, 2026Nothing in our recordNo LGND story, brief or results filing in our record that dayGroup +1.3% did not move with it
+1.3% did not move with itABBV +6.3 · MRK +1.4 · JNJ +1.3 · LLY +0.3
−4.62%
14Jun 18, 2026
Jun 18, 2026Nothing in our recordNo LGND story, brief or results filing in our record that dayGroup −1.8% did not move with it
−1.8% did not move with itJNJ −2.5 · ABBV −2.1 · MRK −1.4 · LLY −1.2
+4.46%
13May 20, 2026
May 20, 2026Before our storiesGroup −0.5% did not move with it
−0.5% did not move with itMRK −1.1 · ABBV −0.7 · JNJ −0.3 · LLY −0.3
+4.80%
12May 8, 2026
May 8, 2026Before our storiesGroup −0.7% did not move with it
−0.7% did not move with itLLY −2.7 · MRK −0.8 · ABBV −0.6 · JNJ −0.5
+5.27%
11May 7, 2026
May 7, 2026ResultsThe first close after a results filing (SEC 8-K, Item 2.02)Group −1.1% did not move with it
−1.1% did not move with itLLY −1.2 · ABBV −1.1 · MRK −1.1 · JNJ −0.9
−9.55%
10Apr 27, 2026
Apr 27, 2026Before our storiesGroup −1.2% did not move with it
−1.2% did not move with itLLY −1.8 · MRK −1.5 · JNJ −0.9 · ABBV −0.7
+4.55%
9Apr 14, 2026
Apr 14, 2026Before our storiesGroup +0.4% did not move with it
+0.4% did not move with itABBV +1.8 · JNJ +0.9 · LLY −0.8 · MRK −0.2
+8.85%
8Apr 13, 2026
Apr 13, 2026Before our storiesGroup −0.9% did not move with it
−0.9% did not move with itLLY −1.1 · MRK −1.1 · ABBV −0.7 · JNJ −0.2
+4.16%
7Mar 27, 2026
Mar 27, 2026Before our storiesGroup −0.1% did not move with it
−0.1% did not move with itLLY −2.1 · ABBV −0.8 · MRK +0.6 · JNJ +0.5
−4.03%
6Mar 13, 2026
Mar 13, 2026Before our storiesGroup −0.2% did not move with it
−0.2% did not move with itABBV −2.5 · LLY +0.8 · MRK −0.3 · JNJ −0.2
−4.05%
5Mar 12, 2026
Mar 12, 2026Before our storiesGroup −0.7% did not move with it
−0.7% did not move with itLLY −2.3 · ABBV −1.0 · JNJ −0.4 · MRK −0.3
−4.41%
4Mar 11, 2026
Mar 11, 2026Before our storiesGroup −0.2% did not move with it
−0.2% did not move with itMRK −0.8 · JNJ −0.3 · ABBV +0.3 · LLY −0.1
+4.22%
3Jan 14, 2026
Jan 14, 2026Before our storiesGroup +1.4% did not move with it
+1.4% did not move with itMRK +2.5 · JNJ +2.3 · ABBV +0.5 · LLY −0.4
+4.11%
2Jan 13, 2026
Jan 13, 2026Before our storiesGroup −0.0% did not move with it
−0.0% did not move with itJNJ +1.9 · MRK −0.8 · LLY −0.3 · ABBV +0.3
−8.72%
1Nov 6, 2025
Nov 6, 2025ResultsThe first close after a results filing (SEC 8-K, Item 2.02)Group +1.2% did not move with it
+1.2% did not move with itMRK +1.6 · LLY +1.3 · ABBV +1.1 · JNJ +0.5
+9.37%

A story on the same day is not a cause, and a group move is not proof either. Group: LLY, JNJ, ABBV, MRK, the largest companies in LGND’s SEC industry; “the same way” means the same direction and at least half as far. Prior-session closes only; not a call, not advice.

The numbers · FY2025, filed

SEC EDGAR

Market cap$6.0B

Revenue$268.1M+60.40%

Net income$124.5M

EPS, diluted$6.13+2886.40%

Operating margin15.3%

Return on equity12.2%

Debt / equity0.03

All filed figures

Snapshot

SEC EDGAR · FY 2025-12-31

SectorHealthcare

Market Cap$6.0B

Enterprise Value$5.9B

Income$124.5M

Sales$268.1M

Book/sh$51.02

Cash/sh$8.77

Dividend TTM$2.50

Payout—

Employees—

IPO—

Quick Ratio21.98

Current Ratio22.23

Debt/Eq0.03

EPS (ttm)$6.13

EPS this Y2886.4%

EPS past 3/5Y—

Sales past 3/5Y11.0%

EPS Y/Y TTM2886.4%

Sales Y/Y TTM60.4%

Shs Outstand19.94M

ROA8.0%

ROE12.2%

ROIC3.7%

Gross Margin—

Oper. Margin15.3%

Profit Margin46.4%

Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.

Revenue by fiscal year

$241.5M

FY21

$196.2M

FY22

$131.3M

FY23

$167.1M

FY24

$268.1M

FY25

Operating leverage — margins

GrossOperatingNet

Financials, annual · income and cash flowSEC EDGAR · open ▸

Financials — annual

SEC EDGAR · last 5 FY · tap a row to explain it

USD	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$241.5M	$196.2M	$131.3M	$167.1M	$268.1M
Gross Profit	—	—	—	—	—
Operating Income	$103.9M	$3.0M	$11.9M	$-22.6M	$41.0M
Net Income	$57.1M	$-33.4M	$52.2M	$-4.0M	$124.5M
Diluted EPS	$3.31	$-1.98	$2.94	$-0.22	$6.13
Operating Cash Flow	$78.8M	$137.8M	$49.6M	$97.0M	$49.4M
Free Cash Flow	$70.0M	$119.9M	$46.1M	$95.2M	$48.9M

Same industry

In the screener →

LLY$1.11T JNJ$653.6B ABBV$467.1B MRK$367.1B ABT$175.3B PFE$163.4B VRTX$133.4B BMY$128.4B

Build basket with LGND Screener

Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.